 |
 Video: What is a Stock Split?
|
|
|
| Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals. According to our TCDA stock split history records, TCDA has had 0 splits. | |
|
TCDA (TCDA) has 0 splits in our TCDA stock split history database.
Looking at the TCDA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TCDA shares, starting with a $10,000 purchase of TCDA, presented on a split-history-adjusted basis factoring in the complete TCDA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/29/2018 |
|
| End date: |
01/23/2023 |
|
| Start price/share: |
$29.90 |
|
| End price/share: |
$0.11 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.64% |
|
| Average Annual Total Return: |
-70.77% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$36.10 |
|
| Years: |
4.57 |
|
|
|
|
|
